Bronchial Asthma 3rd year Medical Students

Slides:



Advertisements
Similar presentations
Predicting risks of asthma recurrence Stephen Watt Consultant in Respiratory and Hyperbaric Medicine Aberdeen Royal Infirmary.
Advertisements

GOLD MANAGEMENT PLAN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
or more simply.. -asthma is a condition of paroxysmal reversible airway obstruction which is characterised by : Airflow limitation ( reversible) Airway.
AsthmaAsthma is a condition characterized by paroxysmal narrowing of the bronchial airways due to inflammation of the bronchi and contraction of the bronchial.
M ANAGING A CUTE A STHMA E XACERBATIONS Cathryn Caton, MD, MS.
Childhood asthma Rod Addis, Vanessa Kerai. Overview Prevalence Prevalence Aetiology Aetiology Pathophysiology Pathophysiology Clinical features Clinical.
นส. นุชนาถ ตั้งเวนิช เจริญสุข รหัส A chronic inflammatory disorder of the airway Airway hyperresponsiveness Recurrent episodes of wheezing,
2008 Guidelines 2.4 DIAGNOSIS IN ADULTS (1) -based on the recognition of a characteristic pattern of symptoms and signs and the absence of an alternative.
Asthma What is Asthma ? V1.0 1997 Merck & ..
BRONCHIAL ASTHMA YOUSEF ABDULLAH AL TURKI MBBS,DPHC,ABFM
Ibrahim Tawhari. Prepared by:. Scernario:  Khalid 14 years old come to the clinic c/o shortness of breath for one day duration.  He is a known asthmatic.
22/06/2011.  Asthma – an introduction (Vanessa)  Diagnosis and management of chronic asthma in line with current BTS guidelines (Dr Lowery)  3 x Case.
Chronic Obstructive Pulmonary Disease and Asthma: All That Wheezes? Clifford Courville, MD Pulmonary, Allergy, and Critical Care.
1 British Guideline on the Management of Asthma BTS/SIGN British Guideline on the Management of Asthma, May 2008 Introduction Diagnosis Non-pharmacological.
British Guideline on the Management of Asthma. Aims Review of current SIGN/BTS guidelines –Diagnosing Asthma –Stepwise management of Asthma –Managing.
Asthma Management Pathophysiology and Management University of Utah Center for Emergency Programs and The Utah Asthma Program.
Diagnosing asthma History & Physical examination Measurements of lung function – Spirometry – Peak expiratory flow Measurements of airway hyperresponsiveness.
Asthma Management Fine Tuning  Maximum control with minimum medication  Start with mild asthma and work up the scale (BTS/SIGN 2004)
Bronchial Asthma  Definition  Patho-physiology  Diagnosis  Management.
Asthma in children Dr Gulamabbas Khakoo BMBCh, FRCPCH
Respiratory COPD/Asthma.
Bronchial Asthma  Definition  Patho-physiology  Diagnosis  Management.
This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.
Assessing Control & Adjusting Therapy in Youths > 12 Years of Age & Adults *ACQ values of 0.76–1.4 are indeterminate regarding well-controlled asthma.
ASTHMA and the updated GINA Global initiative for asthma 2006 R. Louis Department of Pneumology CHU Sart-Tilman Liege.
Asthma Diagnosis: Anatomy and Pathophysiology of Asthma Karen Meyerson, MSN, RN, FNP-C, AE-C Asthma Network of West Michigan April 21, 2009 Acknowledgements:
2008 Guidelines 2.1 DIAGNOSIS IN CHILDREN (1) Asthma in children causes recurrent respiratory symptoms of: wheezing cough difficulty breathing chest tightness.
GOLD Update 2011 Rabab A. El Wahsh, MD. Lecturer of Chest Diseases and Tuberculosis Minoufiya University REVISED 2011.
Component 1: Measures of Assessment and Monitoring n Two aspects: –Initial assessment and diagnosis of asthma –Periodic assessment and monitoring.
Asthma A Presentation on Asthma Management and Prevention.
Diagnosing and Staging Asthma*
Bronchial asthma By Dr. Abdelaty Shawky Assistant professor of pathology.
Exacerbations. Exacerbations An exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond.
Asthma A Presentation on Asthma Management and Prevention.
ASTHMA MANAGEMENT AND PREVENTION PREFACE Asthma affects an estimated 300 million individuals worldwide. Serious global health problem affecting all age.
Asthma Guidelines, Diagnosis and Management Alison Hughes Respiratory Specialist Nurse Solent NHS Trust.
Asthma Lynn Helliwell. Key Facts More than five million people in the UK are being treated for asthma More than five million people in the UK are being.
Definition of asthma Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory.
© Global Initiative for Asthma GINA Global Strategy for Asthma Management and Prevention 2015 This slide set is restricted for academic and educational.
Attaran D, Mashhad university of medical sciences.
Definition Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation and a range of pathological changes in the lung.
Asthma 1 د. ميريانا البيضة. DIAGNOSIS 2 3 Definition of asthma.
Asthma ( Part 1 ) Dr.kassim.M.sultan F.R.C.P. Objectives: 1-Define asthma 2-Identify its aggravating factors 3-Describe its clinical features 4-Illustrate.
Asthma Review of Pathophysiology and Treatment. n definition of asthma –Asthma is a chronic inflammatory disorder of the airways in which many cells &
BRONCHIAL ASTHMA IN CHILDREN lecture for the 6-th year students
Diagnosis of asthma in adolescents and adults D.Anan Esmail Seminar Training Primary Care Asthma+ COPD
Johnathan Grant D.O. FACOI
Chronic Obstructive Pulmonary Disease(COPD)
Jessica Case study.
Eileen G. Holland, Pharm.D., BCPS Associate Professor
Asthma guidelines and treatment
Asthma in the child Dr A Rahman GPST3.
Respiratory disorders
Global Initiative for Asthma (GINA) Teaching slide set 2017 update
Research where it is most needed National Respiratory Strategy
Asthma: In my practice Bangladesh Dr GM Monsur Habib.
BRONCHIAL ASTHMA YOUSEF ABDULLAH AL TURKI MBBS,DPHC,ABFM
Asthma-COPD Overlap Syndrome (ACOS) Challenges Diagnosing ACOS
Bronchial Asthma Dr.Radhakrishna. S. A. Bronchial Asthma Dr.Radhakrishna. S. A.
Asthma Presented by Qassim j. odaa Master M.S.N..
L de Man Dept of Physiotherapy UFS 2012
Global Initiative for Asthma (GINA) What’s new in GINA 2015?
APPROACH TO A PATIENT WITH ACUTE SEVERE ASTHMA
Bronchial Asthma.
Respiratory disorders
Global Initiative for Asthma (GINA) What’s new in GINA 2015?
Drugs Affecting the Respiratory System
G IN A lobal itiative for sthma.
ASTHMA Dr. Saviour K. Assoah (Medicine Dept). OUTLINE Definition Epidemiology Risks / precipitating factors Symptoms and signs Pathophysiology Types of.
Presentation transcript:

Bronchial Asthma 3rd year Medical Students Dr R Nadama MD MRCP(lond) MRCP(UK), FRCP(Lond), EDARM, FCCP

Objectives Definition Epidemiology Pathophysiology Types Diagnosis Management Summary

Asthma Word “asthma” is derived from the ancient Greek word for “panting.” Although asthma is a clearly recognized clinical entity, agreement on a precise definition of asthma has proved elusive.  Asthma has been more often described than defined.

T lymphocytes, macrophages, and epithelial cells. Definition Asthma is a chronic inflammatory disorder of the airways in which many cells play a role: in particular, mast cells, eosinophils, neutrophils. T lymphocytes, macrophages, and epithelial cells. In susceptible individuals, this inflammation causes recurrent episodes of coughing, wheezing, breathlessness, and chest tightness. These episodes are usually associated with widespread but variable airflow obstruction (airway hyper-responsiveness) that is often reversible either spontaneously or with treatment.

Epidemiology Any age, 75% Dx age <7 Remission around puberty Prevalence on the rise. likely Multifactorial Wide geographical variation (4-25%) Females 40% higher prevalence Severe asthma 10 % but morbidity / costs

Saudi Arabia Figures Asthma affects >2 million Saudis Asthma control: 5% were controlled, 31% partially controlled, 64% uncontrolled.

Etiology Although asthma is multifactorial in origin, inflammation is believed to be the cornerstone of the disease and is thought to result from inappropriate immune responses to a variety of antigens in genetically susceptible individuals.

Causes Hygiene Hypothesis Atopy Genetics Smoking – controversial Obesity – New under Ix

Cause - Hygiene Hypothesis

Asthma Types

Types Phenotypes Endotypes Mixed or overlapping features

Asthma Types Early onset (<12years) Late onset (>12years) Childhood-onset asthma a relatively homogeneous group Allergic Asthma (Atopic) Usually a strong allergic Hx FH of asthma. Late onset (>12years) Adult-onset asthmatics are a very mixed group Heterogeneous Late onset – Atopic (34%) have less severe disease. Those with severe disease are less likely to be atopic Non Atopic (52%) have mild-to-moderate persistent asthma Late onset eosinophilic asthma AERD Aspirin Exacerbated Respiratory Disease

History Examination Test Diagnosis History Examination Test

History

(British/SIGN Guidelines Sept 2016)

(British/SIGN Guidelines Sept 2016)

BTS 2014

Differential Diagnosis

Other Illness with wheezing / SOB COPD (Smoker) Heart failure Airway obstruction (Tumors, FB) Vocal cord dysfunction May Coexist and complicate Dx of asthma GERD, OSA, ABPA

Examination

Examination Upper respiratory tract (nasal secretion, mucosal swelling, nasal polyp) Chest (Wheezing or prolonged phase of forced exhalation, Chest hyper-expansion, accessory muscles) Skin (atopic dermatitis, eczema)

Wheezing Wheezing—high-pitched whistling sounds when breathing out A lack of wheezing and a normal chest examination do not exclude asthma

Wheeze

Investigations

Tests Spirometry – Routine Usually if alternate Dx considered Full Lung Functions CXR / CT Chest FBC Airway Hyper-responsiveness tests (If spiro normal)

Asthma Dx – variable airflow limitation Confirm presence of airflow limitation Document that FEV1/FVC is reduced <0.75 (at least once) Confirm variation in lung function or Reversibility Excessive bronchodilator reversibility (FEV1 >12% and >200mL) Excessive diurnal variability twice-daily PEF monitoring

Typical spirometric tracings Volume Flow Volume Normal Asthma (after BD) Asthma (before BD) Normal FEV1 Asthma (after BD) Asthma (before BD) 1 2 3 4 5 6 Time (seconds) Note: Each FEV1 represents the highest of three reproducible measurements

Diagnostic Approach

GINA 2017, Box 1-1 (4/4) Patient with respiratory symptoms Are the symptoms typical of asthma? NO YES Detailed history/examination for asthma History/examination supports asthma diagnosis? Further history and tests for alternative diagnoses Alternative diagnosis confirmed? NO Clinical urgency, and other diagnoses unlikely YES Perform spirometry/PEF with reversibility test Results support asthma diagnosis? Repeat on another occasion or arrange other tests Confirms asthma diagnosis? NO NO YES Empiric treatment with ICS and prn SABA Review response Diagnostic testing within 1-3 months NO YES YES Consider trial of treatment for most likely diagnosis, or refer for further investigations Treat for ASTHMA Treat for alternative diagnosis GINA 2017, Box 1-1 (4/4) © Global Initiative for Asthma

Management

Components of Asthma Management Monitoring Education Control of environmental factors Pharmacologic Rx

Monitoring Symptoms Peak Flow (Home) Spirometry (Clinic) Novel FENO and Sputum eosinophils Assess Severity and Control of asthma

Education Compliance Inhalers techniques Asthma Action plans Specific directions for daily management and for adjusting medications in response to increasing symptoms or decreasing PEFR

Environmental Factors Triggers (Aeroallergens, Irritants) Co-morbid conditions (Obesity, GERD, Rhinitis, ABPA, VCD, stress) Medications (Aspirin, Beta Blockers) Infections (Vaccinations)

Pharmacologic Management

Aims (British/SIGN Guidelines Sept 2016)

GINA assessment of symptom control A. Symptom control In the past 4 weeks, has the patient had: Well-controlled Partly controlled Uncontrolled Daytime asthma symptoms more than twice a week? Yes No None of these 1-2 of these 3-4 of these Any night waking due to asthma? Yes No Reliever needed for symptoms* more than twice a week? Yes No Any activity limitation due to asthma? Yes No Level of asthma symptom control *Excludes reliever taken before exercise, because many people take this routinely GINA 2017, Box 2-2A

Assessment of risk factors for poor asthma outcomes Independent* risk factors for exacerbations include: Ever intubated for asthma Uncontrolled asthma symptoms Having ≥1 exacerbation in last 12 months Low FEV1 (measure lung function at start of treatment, at 3-6 months to assess personal best, and periodically thereafter) Incorrect inhaler technique and/or poor adherence Smoking Elevated FeNO in adults with allergic asthma Obesity, pregnancy, blood eosinophilia Risk factors for exacerbations include: Ever intubated for asthma Uncontrolled asthma symptoms Having ≥1 exacerbation in last 12 months Low FEV1 (measure lung function at start of treatment, at 3-6 months to assess personal best, and periodically thereafter) Incorrect inhaler technique and/or poor adherence Smoking Obesity, pregnancy, blood eosinophilia UPDATED 2017 * Independent of the level of symptom control GINA 2017, Box 2-2B (2/4)

Approach (British/SIGN Guidelines Sept 2016)

Pharmacologic Treatment Relievers Short Acting Beta agonist Preventer Steroids Long acting Beta Agonist and LAMA Leukotriene's receptors Antagonist Theophylline Personalized Medicine eg Anti IgE or Anti IL5

GINA 2017

GINA 2017

Asthma Self Management Communicate and educate patient A written asthma action plan includes all the information you need to look after your asthma well, so you’ll have fewer symptoms and significantly cut your risk of an asthma attack.

Managing exacerbations in acute care settings INITIAL ASSESSMENT A: airway B: breathing C: circulation Are any of the following present? Drowsiness, Confusion, Silent chest NO YES Further TRIAGE BY CLINICAL STATUS according to worst feature Consult ICU, start SABA and O2, and prepare patient for intubation MILD or MODERATE Talks in phrases Prefers sitting to lying Not agitated Respiratory rate increased Accessory muscles not used Pulse rate 100–120 bpm O2 saturation (on air) 90–95% PEF >50% predicted or best SEVERE Talks in words Sits hunched forwards Agitated Respiratory rate >30/min Accessory muscles being used Pulse rate >120 bpm O2 saturation (on air) < 90% PEF ≤50% predicted or best Short-acting beta2-agonists Consider ipratropium bromide Controlled O2 to maintain saturation 93–95% (children 94-98%) Oral corticosteroids Short-acting beta2-agonists Ipratropium bromide Controlled O2 to maintain saturation 93–95% (children 94-98%) Oral or IV corticosteroids Consider IV magnesium Consider high dose ICS If continuing deterioration, treat as severe and re-aassess for ICU ASSESS CLINICAL PROGRESS FREQUENTLY MEASURE LUNG FUNCTION in all patients one hour after initial treatment FEV1 or PEF 60-80% of predicted or personal best and symptoms improved MODERATE Consider for discharge planning FEV1 or PEF <60% of predicted or personal best,or lack of clinical response SEVERE Continue treatment as above and reassess frequently GINA 2017, Box 4-4 (1/4)

INITIAL ASSESSMENT A: airway B: breathing C: circulation Are any of the following present? Drowsiness, Confusion, Silent chest NO YES Further TRIAGE BY CLINICAL STATUS according to worst feature Consult ICU, start SABA and O2, and prepare patient for intubation MILD or MODERATE Talks in phrases Prefers sitting to lying Not agitated Respiratory rate increased Accessory muscles not used Pulse rate 100–120 bpm O2 saturation (on air) 90–95% PEF >50% predicted or best SEVERE Talks in words Sits hunched forwards Agitated Respiratory rate >30/min Accessory muscles being used Pulse rate >120 bpm O2 saturation (on air) < 90% PEF ≤50% predicted or best GINA 2017, Box 4-4 (2/4)

Prefers sitting to lying Not agitated Respiratory rate increased MILD or MODERATE Talks in phrases Prefers sitting to lying Not agitated Respiratory rate increased Accessory muscles not used Pulse rate 100–120 bpm O2 saturation (on air) 90–95% PEF >50% predicted or best SEVERE Talks in words Sits hunched forwards Agitated Respiratory rate >30/min Accessory muscles being used Pulse rate >120 bpm O2 saturation (on air) < 90% PEF ≤50% predicted or best Short-acting beta2-agonists Consider ipratropium bromide Controlled O2 to maintain saturation 93–95% (children 94-98%) Oral corticosteroids Short-acting beta2-agonists Ipratropium bromide Controlled O2 to maintain saturation 93–95% (children 94-98%) Oral or IV corticosteroids Consider IV magnesium Consider high dose ICS GINA 2017, Box 4-4 (3/4)

Short-acting beta2-agonists Consider ipratropium bromide Controlled O2 to maintain saturation 93–95% (children 94-98%) Oral corticosteroids Short-acting beta2-agonists Ipratropium bromide Controlled O2 to maintain saturation 93–95% (children 94-98%) Oral or IV corticosteroids Consider IV magnesium Consider high dose ICS If continuing deterioration, treat as severe and re-assess for ICU ASSESS CLINICAL PROGRESS FREQUENTLY MEASURE LUNG FUNCTION in all patients one hour after initial treatment FEV1 or PEF 60-80% of predicted or personal best and symptoms improved MODERATE Consider for discharge planning FEV1 or PEF <60% of predicted or personal best,or lack of clinical response SEVERE Continue treatment as above and reassess frequently GINA 2017, Box 4-4 (4/4)

Key Messages Asthma is a chronic inflammatory condition associated with significant morbidity and mortality which is preventable and manageable with appropriate treatment and effective patient communication

Key Messages Asthma is a chronic inflammatory condition associated with significant morbidity and mortality which is preventable and manageable with appropriate treatment and effective patient communication

References International Clinical Guidelines GINA, BTS, SINA National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm Smith HR, Irvin CG, Cherniack RM. The utility of spirometry in the diagnosis of reversible airways obstruction. Chest 1992; 101:1577 Gender differences in prevalence, diagnosis and incidence of allergic and non-allergic asthma: a population-based cohort; Thorax 2012;67:625-631 doi:10.1136/thoraxjnl-2011-201249 Al Frayh AR, Shakoor Z, Gad El Rab MO, Hasnain SM. Increased prevalence of asthma in Saudi Arabia. Ann Allergy Asthma Immunol 2001;86:292-6.   [PUBMED]